CD44 and ovarian carcinoma: In line with these observations, we have previously shown that CD44 promotes multidrug resistance and MDR1 stabilization in ovarian cancer cells (95, 96), while STAT3 signaling has been shown to induce MDR1 expression in ovarian, lung and bone cancers, as well as a myeloid leukemia model (97–100).